Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug candidate 177Lu-SN201 ...

According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...

Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

This illustration shows targeted alpha therapy, in which actinium-225 is linked to a targeting molecule that binds to a cancer cell and delivers ...

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month, with leadership changes spanning global giants, clinical-stage biotechs, and specialist pharma companies ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

HVM Racing and its Nuclear Clean Air Energy and Medicine Campaign (NCAEM), together with anchor partners Rev1 Energy and Tracker Technologies, today announced the campaign's return to the NTT INDYCAR ...